3‐Indoxyl Sulfate and O ‐Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer
Cancer Science · 09.11.2026
DOI: 10.1111/cas.70570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 09.11.2026. Verfasst von Kenji Hamada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Science and Technology Agency (JST), Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Esophageal cancer is the seventh most common cancer worldwide, and early detection is crucial for improving long‐term survival. However, reliable noninvasive biomarkers for early‐stage disease remain limited. In this study, we aimed to identify novel biomarkers for early‐stage esophageal cancer through comprehensive metabolomic analyses of plasma and urine samples from patients and healthy individuals. Metabolomic profiling revealed that 3‐indoxyl sulfate (3‐IS) was consistently elevated in both plasma and urine of esophageal cancer patients. As esophageal cancer cells do not directly produce 3‐IS, its elevation may reflect cancer‐associated systemic metabolic alterations. O ‐acetylcarnitine ( O ‐AC) was identified as the most significantly increased metabolite in plasma, and in vitro analyses suggested a possible association with tumor‐related metabolic changes. Receiver operating characteristic analyses (ROC) demonstrated that the combined plasma and urinary 3‐IS model achieved an area under the curve (AUC) of 0.863 in Stage I/II disease, whereas plasma O ‐AC achieved an AUC of 0.902. Bootstrap resampling provided internal validation; however, the discovery and evaluation were performed within the same single‐center cohort. These results suggest that 3‐IS and O ‐AC are promising candidate biomarkers that distinguish patients with esophageal cancer from healthy individuals, but further validation of their disease specificity and diagnostic performance is required in independent multicenter cohorts including clinically relevant disease‐control groups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
- Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
- Gut Environmental Design Group, Kanagawa Institute of Industrial Science and Technology, Kawasaki, Kanagawa, Japan.
- Transborder Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
- Innovative Microbiome Therapy Research Center, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
ORCID-Profile: Yohei Ozawa, Hiroshi Okamoto, Shinji Fukuda, Tomoyoshi Soga, Hozumi Motohashi, Shohei Murakami, Takashi Kamei
Förderung
- Japan Agency for Medical Research and Development
- Japan Science and Technology Agency (JST)
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Hamada, K., Ozawa, Y., Okamoto, H., Fukuda, S., Soga, T., Abe, T., Motohashi, H., Murakami, S., & Kamei, T. (2026). 3‐Indoxyl Sulfate and O ‐Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer. Cancer Science. https://doi.org/10.1111/cas.70570
Vancouver
Hamada K, Ozawa Y, Okamoto H, Fukuda S, Soga T, Abe T, et al. 3‐Indoxyl Sulfate and O ‐Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer. Cancer Science. 2026. doi:10.1111/cas.70570
BibTeX
@article{Hamada2026,
author = {Hamada, Kenji and Ozawa, Yohei and Okamoto, Hiroshi and Fukuda, Shinji and Soga, Tomoyoshi and Abe, Takaaki and Motohashi, Hozumi and Murakami, Shohei and Kamei, Takashi},
title = {3‐Indoxyl Sulfate and O ‐Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70570}
}
EUVIMED